Genprex -- Immunogene Therapy VS NSCLC
Seite 1 von 2 Neuester Beitrag: 05.01.23 09:57 | ||||
| Eröffnet am: | 14.03.19 22:28 | von: centsucher | Anzahl Beiträge: | 34 |
| Neuester Beitrag: | 05.01.23 09:57 | von: Garlicbread . | Leser gesamt: | 18.611 |
| Forum: | Hot-Stocks | Leser heute: | 11 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 > | ||||
https://www.genprex.com/investors/sec-filings/
https://www.genprex.com/news/category/press-releases/
Genprex mit ihrem Hauptproduktkandidat Onkoprex in Phase2
Combining Oncoprex™ With Tarceva®
A phase I/II clinical trial is underway evaluating intravenous Oncoprex in combination with Tarceva® (erlotinib) in stage IIIB/IV lung cancer patients without an activating EGFR mutation and in patients with an activating EGFR mutation whose cancer has progressed on erlotinib therapy.
We believe that the results from the ongoing Phase II trial to date are encouraging. Out of 10 patients, 9 had received 2 or more cycles and were therefore evaluable for response. Four patients had tumor regression. The median duration of response is 3 months. The disease control rate (CR+PR+SD > 8weeks) was 78%, which substantially exceeds the 7% response rate (with no CRs) and 58% disease control rate reported for the LUX-Lung 1 trial, a clinical trial of afatinib in a comparable group of patients.
One patient in the Phase II combination trial had a Complete Response
https://www.genprex.com/clinical-trials/erlotinib-combination/
Studienende :
| Estimated Primary Completion Date : | March 2020 |
| Estimated Study Completion Date : | July 2020 |
Zu bedenken bei den Ansprechraten ist die weit vortgeschrittene Krankheit!
Shares out: 15,1Mio
Über 50% schon vergeben! SEC Filings vom 15.2.19
Optionen
| Boardmail an "centsucher" |
Wertpapier: Genprex Inc |
Optionen
| Boardmail an "Frozenfrog" |
Wertpapier: Genprex Inc |
Wie in #12/#14 schon vermutet, nimmt Genprex jetzt mal einen größeren Schluck aus der Pulle
- Offering 5 Mio. neue Aktien zu je 3,50$ ~ 17,5 Mio. $ Erlös
https://seekingalpha.com/news/...1-genprex-down-17-on-equity-offering
Optionen
| Boardmail an "Vassago" |
Wertpapier: Genprex Inc |
Zweite Fast Track Zulassung für Genprex. Nach 190% gestern dürfte das erstmal ein Multi-Day Runner werden.
https://finance.yahoo.com/news/...ancer-program-scores-142122426.html
AUSTIN, Texas (January 4, 2023) Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprexs gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22-25 in Berlin, Germany and online.
ATTD 2023 presents an ideal opportunity for the results of this important study to be presented to the diabetes community. The data further support the potential of Genprexs novel gene therapy being developed for the treatment of Type 1 diabetes to change the trajectory of this devastating disease, said Mark Berger, MD, Genprexs Chief Medical Officer. Using the expression of Pdx1 and MafA transcription factors, this approach has been shown first in mice and then in non human primate studies to lead to the creation of new beta-like cells that produce insulin and may provide long-term replacement of beta-cells.
The diabetes gene therapy approach is comprised of a novel infusion process that uses endoscopic delivery of an adeno-associated virus (AAV) vector to bring therapeutic genes directly to the pancreas. In models of Type 1 diabetes, these genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the bodys immune system. In Type 2 diabetes, where autoimmunity is not at play, it is believed that using a similar approach the exhausted beta cells will be rejuvenated and replenished.
Presentation Details:
Abstract Number: 203
Abstract Title: Pancreatic Intraductal Infusion of Adeno-Associated Virus To Treat Non-Human Primates in a Toxin-Induced Diabetes Model
Format: Oral Presentation
Presenter: Ranjeet Kalsi, DO, representing the laboratory of George Gittes, MD, Professor of Surgery and Pediatrics and Chief of the Division of Pediatric Surgery, University of Pittsburgh School of Medicine
Time/Date: 1:45 pm Central European Standard Time on Saturday, February 25, 2023
https://www.genprex.com/news/...technologies-treatments-for-diabetes/